Recombinant proteins of Plasmodium malariae merozoite surface protein 1 (PmMSP1): Testing immunogenicity in the BALB/c model and potential use as diagnostic tool

Imagem de Miniatura
Arquivos
art_ELIZARDEZ_Recombinant_proteins_of_Plasmodium_malariae_merozoite_surface_protein_2019.PDF (2.58 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
FOTORAN, Wesley L.
CURADO, Izilda
NETO, Irineu Romero
WUNDERLICH, Gerhard
Citação
PLOS ONE, v.14, n.7, article ID e0219629, 20p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Plasmodium malariae is the third most prevalent human malaria-causing species and has a patchy, but ample distribution in the world. Humans can host the parasite for years without presenting significant symptoms, turning its diagnosis and control into a difficult task. Here, we investigated the immunogenicity of recombinant proteins of P. malariae MSP1. Methods Five regions of PmMSP1 were expressed in Escherichia coli as GST-fusion proteins and immunized in BALB/c mice. The specificity, subtyping, and affinity of raised antibodies were evaluated by enzyme-linked immunosorbent assays. Cellular immune responses were analyzed by lymphoproliferation assays and cytokine levels produced by splenocytes were detected by cytometry. Results We found that N-terminal, central regions, and PmMSP1(19) are strongly immunogenic in mice. After three doses, the induced immune responses remained high for 70 days. While antibodies induced after immunization with N-terminal and central regions showed similar affinities to the target antigens, affinities of IgG against PmMSP1(19) were higher. All proteins induced similar antibody subclass patterns (predominantly IgG1, IgG2a, and IgG2b), characterizing a mixed Th1/Th2 response. Further, autologous stimulation of splenocytes from immunized mice led to the secretion of IL2 and IL4, independently of the antigen used. Importantly, IgG from P. malariae-exposed individuals reacted against PmMSP1 recombinant proteins with a high specificity. On the other hand, sera from P. vivax or P. falciparum-infected individuals did not react at all against recombinant PmMSP1 proteins. Conclusion Recombinant PmMSP1 proteins are very useful diagnostic markers of P. malariae in epidemiological studies or in the differential diagnosis of malaria caused by this species. Immunization with recombinant PmMSP1 proteins resulted in a significant humoral immune response, which may turn them potential component candidates for a vaccine against P. malariae.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/34153
Referências
  1. Ahlborg N, 2000, INFECT IMMUN, V68, P2102, DOI 10.1128/IAI.68.4.2102-2109.2000
  2. Amanfo SA, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1325-3
  3. [Anonymous], ACTA TROP, V100, P54, DOI [10.1016/j.actatropica.2006.09.010, DOI 10.1016/J.ACTATROPICA.2006.09.010]
  4. Antinori S, 2012, MEDITERR J HEMATOL I, V4, DOI 10.4084/MJHID.2012.013
  5. Badiane AS, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-226
  6. Bargieri DY, 2007, MEM I OSWALDO CRUZ, V102, P313, DOI 10.1590/S0074-02762007005000039
  7. Birkenmeyer L, 2010, AM J TROP MED HYG, V82, P996, DOI 10.4269/ajtmh.2010.09-0022
  8. Boivin GP, 2017, J AM ASSOC LAB ANIM, V56, P491
  9. Breukels MA, 2002, CLIN INFECT DIS, V34, P191, DOI 10.1086/338259
  10. Coatney GR, 1971, PRIMATES MALARIA
  11. Collins WE, 2007, CLIN MICROBIOL REV, V20, P579, DOI 10.1128/CMR.00027-07
  12. Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
  13. Curado I, 2006, ACTA TROP, V100, P54, DOI 10.1016/j.actatropica.2006.09.010
  14. DALY TM, 1995, J IMMUNOL, V155, P236
  15. de Oliveira CI, 1999, VACCINE, V17, P2959, DOI 10.1016/S0264-410X(99)00176-0
  16. Dutta S, 2001, INFECT IMMUN, V69, P5464, DOI 10.1128/IAI.69.9.5464-5470.2001
  17. Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765
  18. Epp C, 2003, J CHROMATOGR B, V786, P61, DOI 10.1016/S1570-0232(02)00722-5
  19. Goldblatt D, 1998, J INFECT DIS, V177, P1112, DOI 10.1086/517407
  20. Guimaraes LO, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1238-8
  21. Hirunpetcharat C, 2003, VACCINE, V21, P2923, DOI 10.1016/S0264-410X(03)00132-4
  22. HOLDER AA, 1988, PROG ALLERGY, V41, P72
  23. Hui GS, 2008, INT IMMUNOPHARMACOL, V8, P1012, DOI 10.1016/j.intimp.2008.03.005
  24. Iber D, 2001, AFFINITY MATURATION
  25. Kidd Parris, 2003, Altern Med Rev, V8, P223
  26. Kirchgatter K, 2005, BMJ-BRIT MED J, V331, p76b
  27. Kumar S, 2004, INFECT IMMUN, V72, P949, DOI 10.1128/IAI.72.2.949-957.2004
  28. Langford S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004195
  29. LEVITUS G, 1994, AM J TROP MED HYG, V51, P68, DOI 10.4269/ajtmh.1994.51.68
  30. Li G, 2008, PARASITE IMMUNOL, V30, P315, DOI 10.1111/j.1365-3024.2008.01027.x
  31. Lim KJ, 2004, PARASITOL RES, V92, P384, DOI 10.1007/s00436-003-1009-0
  32. Lima GFMC, 2018, BLOOD TRANSFUS-ITALY, V16, P17, DOI 10.2450/2016.0118-16
  33. Linke A, 1996, EXP PARASITOL, V84, P253, DOI 10.1006/expr.1996.0111
  34. Lopez C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00126
  35. MACDONALD RA, 1988, J IMMUNOL METHODS, V106, P191, DOI 10.1016/0022-1759(88)90196-2
  36. Lima GFMD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150391
  37. Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
  38. MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
  39. Matsumoto S, 2000, VACCINE, V19, P779, DOI 10.1016/S0264-410X(00)00257-7
  40. Medeiros MM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-608
  41. Mehrizi AA, 2011, PARASITE IMMUNOL, V33, P594, DOI 10.1111/j.1365-3024.2011.01331.x
  42. Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520
  43. Muerhoff AS, 2010, CLIN VACCINE IMMUNOL, V17, P1631, DOI 10.1128/CVI.00196-10
  44. Ndungu FM, 2002, PARASITE IMMUNOL, V24, P77, DOI 10.1046/j.0141-9838.2001.00440.x
  45. Near KA, 2002, INFECT IMMUN, V70, P692, DOI 10.1128/IAI.70.2.692-701.2002
  46. Nikolaeva D, 2015, EXPERT REV VACCINES, V14, P653, DOI 10.1586/14760584.2015.993383
  47. Oliveira-Ferreira J, 2004, VACCINE, V22, P2023, DOI 10.1016/j.vaccine.2003.07.021
  48. Priest JW, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2566-0
  49. Reddy SB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032242
  50. Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
  51. Rosa DS, 2004, IMMUNOL LETT, V92, P259, DOI 10.1016/j.imlet.2004.01.006
  52. Rutledge GG, 2017, EMERG INFECT DIS, V23, P1300, DOI 10.3201/eid2308.161582
  53. Sachdeva S, 2006, VACCINE, V24, P2007, DOI 10.1016/j.vaccine.2005.11.041
  54. Sachdeva S, 2004, INFECT IMMUN, V72, P5775, DOI 10.1128/IAI.72.10.5775-5782.2004
  55. Scuracchio P, 2011, REV INST MED TROP SP, V53, P55, DOI 10.1590/S0036-46652011000100010
  56. Singh S, 2003, INFECT IMMUN, V71, P6766, DOI 10.1128/IAI.71.12.6766-6774.2003
  57. Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05
  58. Smith NC, 1998, CHEM IMMUNOL, V70, P144
  59. Soares IS, 1997, INFECT IMMUN, V65, P1606
  60. Steward MW, 1983, ANTIBODY AFFINITY TH
  61. TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8
  62. Versiani FG, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/965841
  63. Vinetz JM, 1998, NEW ENGL J MED, V338, P367, DOI 10.1056/NEJM199802053380605
  64. Visser R, 2016, TRAVEL MED INFECT DI, V14, P644, DOI 10.1016/j.tmaid.2016.08.005
  65. WHITE WI, 1991, INFECT IMMUN, V59, P3547
  66. WHO, 2015, WORLD MAL REP 2015

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/49
Artigos e Materiais de Revistas Científicas - ODS/03